Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
about
Present and Future Therapies in Neuromyelitis Optica Spectrum DisordersImmunoinflammatory diseases of the central nervous system - the tale of two cytokines.Therapeutic options in neuromyelitis optica spectrum disorders.What's new in neuromyelitis optica? A short review for the clinical neurologist.
P2860
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
@en
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
@nl
type
label
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
@en
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
@nl
prefLabel
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
@en
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
@nl
P2093
P2860
P356
P1433
P1476
Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.
@en
P2093
Ann-Sophie Lauenstein
Eckart Lensch
Mark Stettner
P2860
P356
10.1136/BCR-2013-202939
P577
2014-03-26T00:00:00Z